1 November 2017 - The National Institute for Health and Care Excellence is recommending Roche’s Tecentriq for use within the Cancer Drugs Fund to treat advanced urothelial cancer in certain circumstances.

In final draft guidelines, Tecentriq (atezolizumab) is being backed for use in patients whose urothelial cancer has not yet been treated and who cannot have cisplatin-based chemotherapy.

Initially, the Institute’s appraisal committee ruled that the drug was not a cost effective option for people who had already had chemotherapy, but that there was potential for the drug to be both clinically and cost effective for those who had not been treated.

Read Pharma Times article